利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.022 秒)

    DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO
    1.
    发明申请
    DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO 有权
    检测和定量生物体内的生物体形成

    公开(公告)号：US20100111861A1

    公开(公告)日：2010-05-06

    申请号：US12610871

    申请日：2009-11-02

    申请人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    发明人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    IPC分类号： A61K51/04

    CPC分类号： A61K51/0406 ,  A61K49/0008 ,  G01N33/5011

    摘要： A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject.

    摘要翻译： 测量抗癌剂在产生受试者的癌细胞的DNA中的脱碱性（AP）位点的功效的方法包括向受试者施用在至少一种癌细胞中产生AP位点的抗癌剂和AP内切核酸酶抑制剂探针。 AP内切核酸酶抑制剂探针包括用于检测受试者中的探针的检测部分。 然后测量与受试者的癌细胞结合的探针的量。 与受试者的癌细胞结合的探针的量指示抗癌剂在产生受试者的癌细胞中的AP位点的功效。

    Detection and quantification of abasic site formation in vivo
    3.
    发明授权
    Detection and quantification of abasic site formation in vivo 有权
    体内无碱基位点形成的检测和定量

    公开(公告)号：US08367332B2

    公开(公告)日：2013-02-05

    申请号：US12610871

    申请日：2009-11-02

    申请人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    发明人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    IPC分类号： C12Q1/68 ,  C07H21/00

    CPC分类号： A61K51/0406 ,  A61K49/0008 ,  G01N33/5011

    摘要： A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject.

    摘要翻译： 测量抗癌剂在产生受试者的癌细胞的DNA中的脱碱性（AP）位点的功效的方法包括向受试者施用在至少一种癌细胞中产生AP位点的抗癌剂和AP内切核酸酶抑制剂探针。 AP内切核酸酶抑制剂探针包括用于检测受试者中的探针的检测部分。 然后测量与受试者的癌细胞结合的探针的量。 与受试者的癌细胞结合的探针的量指示抗癌剂在产生受试者的癌细胞中的AP位点的功效。

    Measuring content item effectiveness
    9.
    发明授权
    Measuring content item effectiveness 有权
    测量内容项目有效性

    公开(公告)号：US09031861B1

    公开(公告)日：2015-05-12

    申请号：US13242772

    申请日：2011-09-23

    申请人： Lili Liu ,  Chao Cai ,  Paul Liu ,  Sissie Ling-le Hsiao ,  Karl Pfleger

    发明人： Lili Liu ,  Chao Cai ,  Paul Liu ,  Sissie Ling-le Hsiao ,  Karl Pfleger

    IPC分类号： G06Q30/00 ,  G06Q30/02

    CPC分类号： G06Q30/0205

    摘要： Methods, systems, and computer program products are provided for measuring effectiveness of content items included in a campaign. One example method includes providing a corpus of campaigns, where a campaign defines parameters for presentation that specify circumstances under which content items are presented to users in response to requests. The corpus is filtered by identifying one or more candidate campaigns, where each of the identified candidate campaigns is associated with a geographic region and includes one or more constraints that permit pausing distribution of content items without compromising campaign goals. For each candidate campaign, one or more experimental geographic locations included in the geographic region are determined that are substantially representative of the region. Presentation of at least one of the content items is paused for a time period, and content item effectiveness is measured by comparing resource conversions for experimental and control geographic locations.

    摘要翻译： 提供了方法，系统和计算机程序产品，用于衡量活动中包含的内容项目的有效性。 一种示例性方法包括提供广告系列语料库，其中活动定义用于呈现的参数，其指定响应于请求将内容项呈现给用户的情况。 通过识别一个或多个候选活动来筛选语料库，其中每个所识别的候选活动与地理区域相关联，并且包括允许在不影响活动目标的情况下暂停分配内容项目的一个或多个约束。 对于每个候选活动，确定包括在地理区域中的一个或多个实验地理位置，其基本上代表该区域。 至少一个内容项的呈现暂停一段时间，通过比较实验和控制地理位置的资源转换来测量内容项有效性。

    Coronary vein dimensional sensor and fixation apparatus
    10.
    发明授权
    Coronary vein dimensional sensor and fixation apparatus 有权
    冠状静脉尺寸传感器和固定装置

    公开(公告)号：US08818507B2

    公开(公告)日：2014-08-26

    申请号：US12431301

    申请日：2009-04-28

    申请人： Lili Liu ,  Allan C. Shuros

    发明人： Lili Liu ,  Allan C. Shuros

    IPC分类号： A61N1/362 ,  A61B5/11 ,  A61N1/05 ,  A61B5/02 ,  A61N1/365 ,  A61B5/00 ,  A61B5/0215

    CPC分类号： A61N1/057 ,  A61B5/02 ,  A61B5/02028 ,  A61B5/0215 ,  A61B5/1076 ,  A61B5/1107 ,  A61B5/686 ,  A61B2562/0261 ,  A61N1/3627 ,  A61N1/36578 ,  A61N2001/0585

    摘要： A system and method for estimating a hemodynamic performance parameter value of a patient's heart. The system includes a pulse generator and a medical electrical lead implanted partially within a coronary vein of the heart. The lead includes at least one sensor located within the coronary vein configured to generate a signal indicative of at least one dimensional parameter of the coronary vein. Changes in the dimensional parameter during one or more cardiac cycles are measured. The hemodynamic performance parameter is estimated based on the change in the dimensional parameter of the coronary vein.

    摘要翻译： 一种用于估计患者心脏的血液动力学性能参数值的系统和方法。 该系统包括部分地植入心脏冠状静脉内的脉冲发生器和医用电线。 引线包括位于冠状静脉内的至少一个传感器，其构造成产生指示冠状静脉的至少一维参数的信号。 测量一个或多个心动周期内尺寸参数的变化。 基于冠状静脉尺寸参数的变化估计血流动力学性能参数。